Prevalence of Depression among Iranian Patients with Beta-Thalassemia Major: A Systematic Review and Meta-analysis

Zahra Jaafari1, MSc; Nasrin Sadidi1, MSc; Zahra Abdolahinia1, MSc; Armita Shahesmaeili2, MD, PhD

1Student Research Committee, Kerman University of Medical Sciences, Kerman, Iran; 2HIV/STI Surveillance Research Center, and WHO Collaborating Center for HIV Surveillance, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, Iran

Correspondence: Armita Shahesmaeili, MD, PhD; Postal address: Kerman University of Medical Sciences, Medical University Campus, Haft-Bagh Hwy., Postal code: 76169-13565, Kerman, Iran
Tel: +98 34 31325423
Fax: +98 34 31325830
Email: a.shahesmaeili@kmu.ac.ir
Received: 04 April 2020
Revised: 22 August 2020
Accepted: 31 August 2020

Abstract

Background: Patients with beta-thalassemia (BT) are susceptible to psychological disorders such as depression. The present study was conducted to estimate the pooled prevalence of depression among patients with BT in Iran.

Methods: Domestic and international databases were searched for relevant articles published from 1991 until June 2019. We searched international databases such as Scopus, ISI, and Embase; Iranian databases such as SID, Magiran, and IranDoc; and Google Scholar and PubMed search engines. The MeSH keywords used were “depression”, “mental health”, “depressive disorder”, “thalassemia”, “beta-thalassemia major”, “prevalence”, “epidemiology”, and “Iran”. Relevant cross-sectional or cohort studies were included in the analysis. Cochran’s Q test and the I² index were used to assess heterogeneity. The pooled prevalence and its 95% confidence interval (CI) were calculated using “metaprop” commands in Stata 14. In cases, where the I² statistic was greater than 50%, the random-effects model was used.

Results: Eighteen eligible studies were included. The pooled prevalence of depression was 42% (95% CI: 33% to 52%), whereas the pooled prevalence of mild, moderate, severe, and extremely severe depression was 16% (95% CI: 11% to 22%), 13% (95% CI: 9% to 18%), 13% (95% CI: 9% to 17%), and 3% (95% CI: 0% to 8%), respectively. The pooled prevalence of depression in moderate- and high-quality studies was 45% (95% CI: 29% to 61%), and 39% (95% CI: 27% to 51%), respectively.

Conclusion: The high prevalence of depression highlights the urgent need for the establishment of interventions for the prevention, early detection, and treatment of depression among Iranian patients with BT.

Keywords ● Depression ● Thalassemia ● Prevalence ● Meta-analysis ● Iran

Introduction

Thalassemia is the most common form of inherited anemia worldwide.1 Beta-thalassemia (BT) major is a thalassemia type characterized by anomalies in the synthesis of the beta chains of hemoglobin, which results in various phenotypes ranging from clinically asymptomatic to severe anemia.2 The World Health Organization (WHO) in 2019 reported that around 50,000 infants were born with BT every year.3 Iran, with a thalassemia gene
prevalence rate of 4%, is among the countries located on the thalassemia belt. It is estimated that there are between two to three million BT carriers and 25,000 patients in Iran.4

Patients with BT suffer from various physical and psychiatric problems. Although various aspects of physical health have been considered in these patients, little attention has been paid to their psychological status.5 The psychological health of patients with BT is of great importance, as it has been linked to their treatment compliance and long-term survival. Depression is the most common psychiatric disorder among these patients6 and could occur due to the chronic nature of the disease, prolonged treatment periods, expectations of premature death, changes in appearance, and feelings of deprivation.7 Depression may cause sadness, loss of interest or pleasure, feelings of guilt or low self-esteem, sleep or appetite disorders, feelings of tiredness, and poor concentration in affected patients.8 The prevalence of depression among patients with BT varies from 10% to 35% in different regions of the world.1, 9-13 In Iran, there is a huge variation in the prevalence of depression in this population. It is reported that 12% to 100% of Iranian patients with BT experience depression.14-16 Previous studies in some regions of Iran have shown that patients with BT have a low quality of life, and a high percentage of them suffer from moderate-to-severe depression, anxiety, and stress.17, 18 As BT is a relatively rare disease, most studies conducted on this population have small sample sizes, which in turn decrease the precision of estimates. Accordingly, the main objective of this systematic review and meta-analysis was to assess the prevalence of depression among Iranian patients with BT. Furthermore, we addressed factors that may introduce heterogeneity in the prevalence. The results of this review may be beneficial to policy-making regarding the early detection of depression in this population.

Materials and Methods

Study Protocol

The present study followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines.19 The search steps, the selection of studies, quality assessment, and data extraction were independently performed by two researchers (J. Z. and A. Z.) to avoid bias, and in the case of controversies, the issue was referred to a third person (Sh. A.).

Search Strategy

Google Scholar and PubMed search engines and Scopus, Web of Science (ISI), and Embase databases were searched to find English articles. Additionally, Iranian databases such as Scientific Information Database (SID), Magiran, and the Iranian Research Institute for Information Science and Technology (IranDoc) were searched to find Farsi articles. The search date was restricted to articles published from 1991 until June 2019. The key Medical Subject Headings (MeSH) were combined using Boolean operators: (depression OR "mental health« OR "depressive disorder" OR "mental health") AND (thalassemia OR "beta-thalassemia major") AND (prevalence OR epidemiology) AND (Iran).

Inclusion and Exclusion Criteria

Cross-sectional or cohort studies that reported the prevalence of depression in individuals with BT and were published in either English or Farsi were eligible. Studies were excluded, if they had the following criteria: 1) they were published before 1991, 2) the prevalence was not reported or could not be calculated based on the data (e.g., studies that only reported the mean depression score), 3) their full-text was inaccessible, and 4) they were duplicated. Two independent reviewers (S. N. and A. Z.) meticulously scanned all the titles, abstracts, and keywords of every published article for their relevance and eligibility. Any disagreement between the two reviewers was resolved by further investigation and discussion among the authors. If the information in the title or abstract was insufficient, the full text was reviewed.

Quality Assessment

For the quality assessment of the articles, the Newcastle-Ottawa Scale (NOS) checklist was used.20 This checklist contains seven items in three sections: 1) Selection of the Study (four items), 2) Comparability (one item), and 3) Outcome (two items). In this study, two authors (A. Z. and S. N.) reviewed the full text of the articles. Studies with NOS scores of seven or greater were regarded as high-quality, studies with a score of 5-6 were considered moderate-quality, and studies with a score of less than five were deemed poor-quality and were excluded from the meta-analysis.

Data Extraction

The data extraction procedure was performed
by two reviewers (J. Z. and Sh. A.) using a digital data extraction form. The extracted data were "study location and setting", "publication year", "participants' characteristics" (gender and age), "sample size", "reported prevalence of depression and its 95% confidence interval (CI) ", "year of study", "type of study", and "type of questionnaire used for depression measurement".

**Definition**

The main outcome was defined as the diagnosis of depression in patients with BT based on the following questionnaires: the Beck Depression Inventory (Beck),21, 22 the General Health Questionnaire (GHQ-28),23 the Depression Anxiety Stress Scale (DASS),24 the Hospital Anxiety Depression Scale (HADS),22 the Children Depression Inventories (CDI),25 the Children Depression Scale (CDS),26 and the Kiddie-SadS (K-SADS).27

**Statistical Analysis**

Pooled prevalence was calculated using the "metaprop" command in Stata software, version 14 (StataCorp LP, 1985–2015, USA). The standard error of prevalence was calculated for each study based on the binomial distribution formula. For the assessment of heterogeneity across the studies, Cochran's Q test and the $P$ statistic were calculated. For $P$ values over 50%, the random-effects model was employed to estimate the pooled measures and 95% CIs. The effect of heterogeneity on depression prevalence was addressed through sub-groups analyses based on geographical regions, quality of studies, and type of questionnaire. In addition, a meta-regression model was used to control the effect of geographical regions, quality of studies, and type of questionnaire on depression prevalence. The possibility of publication bias was addressed through the depiction of a funnel plot illustrating the standard error. All the analyses were performed using Stata software, version 14 (Stata Corp LP, 1985-2015, USA), and $P$ values of less than 0.05 were considered significant. The funnel plot was drawn using Microsoft MedCalc Software, version 19.1.7 (MedCalc software Ltd., Ostend, Belgium).

**Results**

**Literature Search Result**

The initial search identified 1175 articles, of which 385 duplicates were excluded. The

![Flow Diagram](flow_diagram.png)
remaining 790 studies underwent title and abstract screening, which resulted in the identification of 43 eligible articles. At this stage, 10 articles were excluded, because their full-text was inaccessible. After the review of the full text of the remaining 33 articles, 18 articles with medium or high quality were entered into the meta-analysis process (figure 1). Overall, these articles recruited 3053 Iranian patients at a mean age of 22.21 years (95% CI: 19.46% to 24.95%). The sample size of the studies varied from 33 to 480 patients. The most commonly used type of questionnaire was Beck (35%) (table 1).

**The Pooled Prevalence of Depression**

The overall pooled prevalence (95% CI) of depression among patients with BT was 42% (95% CI: 33% to 52%) (figure 2). The sensitivity analysis for the prevalence of depression showed that after the application of the leave-one-out method, the result was still robust (figure 3).

**Subgroup Analysis Based on the Geographical Region**

The subgroup analysis according to the geographical region is shown in table 2. The south of Iran had the highest pooled prevalence of depression (50% [95% CI: 44% to 56%]), followed by east (39% [95% CI: 36% to 43%]), center (33% [95% CI: 20% to 48%]), and north (30% [95% CI: 13% to 50%]) (table 2). Since just one study was performed in the west of Iran, the calculation of the pooled prevalence for this region was impossible.

**Table 1: Characteristics of the 18 studies recruited in the current systematic and meta-analysis of depression among Iranian patients with beta-thalassemia major**

| Author                  | Publication Year | Study Design | Place        | Sample Size | Age (mean±SD) | Questionnaire | Quality Scores (NOS) | Prevalence of Depression (%) |
|-------------------------|------------------|--------------|--------------|-------------|---------------|---------------|----------------------|-----------------------------|
| Hooshmandi and colleagues7 | 2015             | Cross-sectional | Bushehr      | 177         | 23.45±5.59    | Beck          | 7                    | 45                          |
| Shafiee and colleagues28 | 2014             | Cross-sectional | Tehran       | 56          | -             | Beck          | 6                    | 38                          |
| Naderi and colleagues16 | 2012             | Cross-sectional | Zahedan      | 164         | 18.70±2.20    | GHQ-28        | 7                    | 12                          |
| Salehi and colleagues19 | 2014             | Cross-sectional | Gorgan       | 163         | 19.60±5.30    | GHQ-28        | 7                    | 40                          |
| Poormansouri and colleagues14 | 2016         | Cross-sectional | Ahvaz        | 142         | 25±5.13       | DASS          | 6                    | 60                          |
| Addib-Hajbaghery and colleagues17 | 2015   | Cross-sectional | Ahvaz        | 173         | 23.34±5.90    | DASS          | 8                    | 58                          |
| Maheri and colleagues20 | 2018             | Cross-sectional | Tehran       | 389         | 30.23±8.30    | HADS         | 7                    | 20                          |
| Azizzadeh Forouzi and colleagues14 | 2015      | Cross-sectional | Kerman       | 480         | 22.60±4.50    | DASS          | 7                    | 51                          |
| Mohammadzadeh and colleagues31 | 2018        | Cross-sectional | Bandar Abbas | 264         | -             | Beck          | 8                    | 42                          |
| Izadyar and colleagues22 | 2006             | Cross-sectional | Tehran       | 135         | -             | CDI          | 6                    | 26                          |
| Izadyar and colleagues22 | 2006             | Cross-sectional | Tehran       | 33          | -             | Beck         | 6                    | 12                          |
| Ghanizadeh and colleagues6 | 2006             | Cross-sectional | Shiraz       | 110         | -             | K-SADS       | 7                    | 49                          |
| Moafi and colleagues21 | 2008             | Cross-sectional | Isfahan      | 50          | 14.80±2.85    | Beck         | 5                    | 52                          |
| Haji Seyedjavadi and Shafikhani34 | 2017        | Cross-sectional | Qazvin       | 147         | -             | HADS         | 5                    | 59                          |
| Ghafari Saravi and colleagues25 | 2004        | Cross-sectional | Sari         | 165         | -             | CDS          | 6                    | 14                          |
| Aziznejad and colleagues26 | 2008            | Cross-sectional | Babol        | 100         | -             | Beck         | 5                    | 39                          |
| Hashemi and colleagues37 | 2012             | Cross-sectional | Yazd         | 34          | -             | Beck         | 5                    | 29                          |
| Marvasti and colleagues24 | 2006             | Cross-sectional | Shiraz       | 208         | -             | Beck         | 5                    | 47                          |
| Khamoushi and colleagues38 | 2015            | Cross-sectional | Kermanshah   | 63          | -             | DASS         | 6                    | 100                         |

*Newcastle-Ottawa Scale; Proportion test was used by “metaprop” command in Stata software. Beck Depression Inventory; General Health Questionnaire; Depression Anxiety Stress Scale; Hospital Anxiety Depression Scale; Children Depression Inventories; Kiddie-Sads; Children Depression Scale
Prevalence of depression among Iranian patients with BT

**Subgroup Analysis Based on Questionnaires**

According to the type of questionnaires used, the lowest pooled prevalence was estimated for studies that utilized GHQ-28 (24% [95% CI: 20% to 29%]), while the highest pooled prevalence was estimated for studies that used DASS (72% [95% CI: 49% to 90%]) for the detection of depression (table 2). The fact that only one study used the CDS questionnaire precluded an estimation of the pooled prevalence based on this questionnaire.

**Subgroup Analysis Based on the Quality of Studies**

The pooled prevalence of depression in high-quality studies (39% [95% CI: 27% to 51%]) was lower than that in moderate-quality studies (45% [95% CI: 29% to 61%]) (table 2).

**Subgroup Analysis Based on the Intensity of Depression**

The pooled prevalence of mild, moderate, severe, and extremely severe depression in Iranian patients with BT was 16% (95% CI: 11% to 22%), 13% (95% CI: 9% to 18%), 13% (95% CI: 9% to 17%), and 3% (95% CI: 0% to 8%), respectively (table 2).

**Meta-regression**

Based on the meta-regression, the pooled prevalence of depression did not vary by geographical region (meta-regression Figure 2).
coefficient: $-0.022$ [95% CI: $-0.100\%$ to $0.054\%$, $P=0.542$]), quality of studies (meta-regression coefficient: $0.011$ [95% CI: $-0.162\%$ to $0.185\%$, $P=0.889$]), and type of questionnaires (meta-regression coefficient: $-0.017$ [95% CI: $-0.069\%$ to $0.034\%$, $P=0.485$]).

**Publication Bias**

A funnel plot was employed to assess the publication bias (figure 4). Asymmetry in the plot is indicative of publication bias.

**Discussion**

To the best of our knowledge, this study is the first systematic review and meta-analysis on the prevalence of depression among patients with BT. We showed that nearly half of Iranian patients with BT suffer from depression, with the prevalence varying from 30% to 50% in different regions of the country.

We found that approximately one out of two patients with BT in Iran had depression. There is no similar review in other countries of the Eastern Mediterranean Region (EMR); we, however, compared our results with those of the original studies on patients with BT in Lebanon (35%), Egypt (32.1%), and Iran’s western neighbor, Turkey (20.5%), indicating that the prevalence of depression in Iranian patients is...
higher. This difference may be due to cultural and ethnic differences, diversities in the quality of prevention, and treatment services in different countries. The role of cultural differences in the expression of depression and psychological disorders has been well-considered in previous studies. Indeed, the association between the cultural and social backgrounds of a community with the emotional characteristics of individuals may result in differences in the expression of depression. Furthermore, stigma attached to psychological disorders, including depression, may result in the under-reporting of these disorders in some communities.

A comparison of our result with the rate in the general population indicates that the prevalence of depression is higher in patients with BT. In a review article conducted in 2016, the pooled prevalence of depression in the Iranian general population was estimated to be 37.2% in the studies that used the Beck questionnaire and 9% in the investigations that utilized the Symptom Checklist-90 (SCL-90) questionnaire. Various factors may explain the higher prevalence of depression in patients with BT. BT is a disabling chronic disease, and the feeling of being different may predispose the affected population to depression. Changes in the physical appearance of patients occurring as a result of iron overload or bone expansion may decrease their self-esteem, which is followed by depression. Besides, a case study suggested a link between BT and depression, which may be implicative of genetic susceptibility to depression in patients with BT. Patients with BT, who suffer from depression may face difficulties in all aspects of life. Depression in this population may lead to weakness in education and job performance, social isolation, lack of independence, and reduced physical ability.

Regarding the intensity of depression, mild depression was the most common (16%) among patients with BT, followed by moderate (13%), severe (13%), and extremely severe (3%) depression. Concerning prevention and early diagnosis, the detection of patients at the early stages of depression and reducing the intensity, duration, and frequency of depressive symptoms, before progression to the late stages of the disease are key interventions in controlling the disease in these patients and should be reinforced in future planning.

There was a high level of heterogeneity in the findings of different studies. We tried to address this issue using the random-effects model, doing a subgroup analysis, and entering the possible sources of heterogeneity as a variable in a meta-regression model. In the subgroup analysis, we observed a geographical variation in the prevalence of depression. Since only one study was conducted in the west of Iran, estimating the pooled prevalence for this region was not possible. Considering other regions, the highest prevalence was related to the south of Iran (50%), while the lowest prevalence was related to the north of Iran (30%). Differences in ethnicity, climates, socioeconomic factors, quality of health care, and access to services may explain this variation. Additionally, the subgroup analysis based on the quality of studies did not substantially affect the prevalence. The prevalence in high- and moderate-quality articles was 39% and 45%, which is close to the overall estimate of 42%. Nonetheless, a comparison of the type of instrument used, the pooled prevalence of depression extensively varied from 24% (for GHQ-28) to 72% (for DASS). Nevertheless, in the meta-regression, none of the mentioned variables (geographical region, type of instrument, and study quality) explained the heterogeneity in the prevalence reported in different studies. Still, lack of appropriate power due to the low number of the included studies compared with the number of predictors may explain the non-significant results of the meta-regression. Likewise, as the number of studies in most subgroups was low, the results of the subgroup analysis should be interpreted with caution. It is also still possible that other unobserved/unmeasured factors such as the sampling method, sex, and gender distribution caused bias in the design and implementation of the study. Significant variations in the prevalence of depression in different populations may be responsible for the observed heterogeneity.

We would like to acknowledge the limitations of the present study. Firstly, we did not adjust the estimated prevalence based on the size of the target population. Secondly, as the prevalence based on the age, gender, and marital status of participants were not reported in most studies, we did not conduct a subgroup analysis based on these variables. Thirdly, as national databases are insensitive to Boolean operators, we could not combine the keywords to search in Iranian databases. Fourthly, because of the possibility of publication bias, the estimated prevalence may not accurately show the real status of depression in patients with BT. Finally, heterogeneity was high across studies. We tried to address this issue by performing a meta-regression, a subgroup analysis, and the random-effects model to estimate the pooled prevalence. However, considering the low number of included studies, the findings should be interpreted with caution.
Conclusion

The high prevalence of depression among Iranian patients with BT is worrisome. Therefore, effective strategies should be formulated in relation to the prevention and early detection of depression in these patients. Routine screening, appropriate education of patients’ families and caregivers, and the integration of mental health services with medical services available for these patients may be appropriate strategies to reduce the burden of depression in this population.

Acknowledgement

We acknowledge Kerman University of Medical Sciences, Kerman, Iran, for its financial support (grant number: 98000517).

Conflict of Interest: None declared.

References

1 Aydinok Y. Thalassemia. Hematology. 2012;17 Suppl 1:S28-31. doi: 10.1179/102453312X13336169155295. PubMed PMID: 22507773.
2 Galanello R, Origa R. Beta-thalassemia. Orphanet J Rare Dis. 2010;5:11. doi: 10.1186/1750-1172-5-11. PubMed PMID: 20492708; PubMed Central PMCID: PMCPMC2893117.
3 Organization WH. Thalassaemia patients have renewed hope through support provided by the Emergency Health and Nutrition Project. Geneva: World Health Organization. 2019.
4 RezaeeAR, BanoeiMM, KhalilieE, Houshmand M. Beta-Thalassaemia in Iran: new insight into the role of genetic admixture and migration. ScientificWorldJournal. 2012;2012:635183. doi: 10.1100/2012/635183. PubMed PMID: 23319887; PubMed Central PMCID: PMCPMC359370.
5 Jain M, Bagul AS, Porwal A. Psycho-social problems in thalassemic adolescents and young adults. Chronicles of young scientists. 2013;4:21-3. doi: 10.4103/2229-5186.108800.
6 Ghanizadeh A, Khajavian S, Ashkani H. Prevalence of psychiatric disorders, depression, and suicidal behavior in child and adolescent with thalassemia major. J Pediatr Hematol Oncol. 2006;28:781-4. doi: 10.1097/01.mph.0000243665.79303.9e. PubMed PMID: 17164645.
7 Mirzaei K. The relationship between social support and depression in patients with thalassemia major in Bushehr, Iran. Nursing of the Vulnerables. 2015;2:1-14.
8 Organization WH. Depression and other common mental disorders: global health estimates. Geneva: World Health Organization, 2017.
9 Az-zahra WF, Mardhiyah A, Nurhidayah I. The Depression Categories of Adolescent with Beta-Thalassemia Major. Journal of Nursing Care. 2019;2. doi: 10.24198/jnc.v2i1.20162.
10 Khoury B, Musallam KM, Abi-Habib R, Bazzi L, Ward ZA, Succar J, et al. Prevalence of depression and anxiety in adult patients with beta-thalassemia major and intermediate. Int J Psychiatry Med. 2012;44:291-303. doi: 10.2190/PM.44.4.a. PubMed PMID: 23885513.
11 Lyrakos G, Drossou-Servou M, Vini D, Aslani H, Spinaris V. 1467–Symptoms of depression, anxiety and stress in patients with thalassemia in a greek transfusion center. European Psychiatry. 2013;28:1. doi: 10.1016/S0924-9338(13)76495-2.
12 Mednick L, Yu S, Trachtenberg F, Xu Y, Kleinert DA, Giardina PJ, et al. Symptoms of depression and anxiety in patients with thalassemia: prevalence and correlates in the thalassemia longitudinal cohort. Am J Hematol. 2010;85:802-5. doi: 10.1002/ajh.21826. PubMed PMID: 20806230; PubMed Central PMCID: PMCPMC4251654.
13 Yahia S, El-Hadidy MA, El-Gilany AH, Anwar R, Darwish A, Mansour AK. Predictors of anxiety and depression in Egyptian thalassemic patients: a single center study. Int J Hematol. 2013;97:604-9. doi: 10.1007/s12185-013-1322-z. PubMed PMID: 23595950.
14 Ramazani T, Safarizadeh M, Alimirzaei R, Rahbarifar S, Fatemi M. Relationship between quality of life and psychological disorders of patients with thalassemia. Scientific Journal of Iran Blood Transfus Organ. 2015;11:362-72.
15 Khamoushi F, Ahmadi SM, Karami-Matin B, Ahmadi-Jouybari T, Mirzaei-Alavijeh M, Atae M, et al. Prevalence and socio-demographic characteristics related to stress, anxiety, and depression among patients with major thalassemia in the Kermanshah County. J Biol Today’s World. 2015;4:79-84. doi: 10.15412/J.JBTW.01040304.
16 Naderi M, Hormozi MR, Asgharif M, Emamzadeh. Evaluation of Mental Health and Related Factors among Patients with Beta-thalassemia Major in South East of Iran. Iran J Psychiatry. 2012;7:47-51. PubMed PMID: 23056118; PubMed Central PMCID:
Prevalence of depression among Iranian patients with BT

17 Adib-Hajbaghery M, Ahmadi M, S P. Health Related Quality of Life, Depression, Anxiety and Stress in Patients with Beta-Thalassemia Major. Iran J Ped Hematol Oncol. 2015;5:193-205. PubMed PMID: 26985352; PubMed Central PMID: PMCPMC4779154.

18 Poormansouri S, Ahmadi M, Shariati A, Keikhaei B. Quality of life, depression, anxiety and stress in over-18-year-old patients with beta-thalassemia major. Scientific Journal of Iran Blood Transfus Organ. 2016;13:72-82.

19 Moher D, Shamseer L, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4:1. doi: 10.1186/2046-4053-4-1. PubMed PMID: 25554246; PubMed Central PMCID: PMCPMC4320440.

20 Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa: Ottawa Hospital Research Institute. c2011. Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp

21 Garcia-Batista ZE, Guerra-Pena K, Cano-Vindel A, Herrera-Martinez SX, Medrano LA. Validity and reliability of the Beck Depression Inventory (BDI-II) in general and hospital population of Dominican Republic. PLoS One. 2018;13:e0199750. doi: 10.1371/journal.pone.0199750. PubMed PMID: 29958268; PubMed Central PMCID: PMCPMC6025862.

22 Loosman WL, Siegert CE, Korzec A, Honig A. Validity of the Hospital Anxiety and Depression Scale and the Beck Depression Inventory for use in end-stage renal disease patients. Br J Clin Psychol. 2010;49:507-16. doi: 10.1348/014466509X477827. PubMed PMID: 20021730

24 Izadyar M, Sedighipourand L, Jafariieh H, Fatahi F. Evaluation Of compliance To Iron Chelation Therapy With Defe-Roxamine In Patients With Major Thalassemia In Iran In 2004. Tehran University Medical Journal TUMS Publications. 2006;64:180-8.

25 Moafi A, Mobarakgi K, Taheri SS, Heidarzadeh A, Shahabi I, Majidi F. Zinc in thalassemic patients and its relation with depression. Biol Trace Elem Res. 2008;123:8-13. doi: 10.1007/s12011-008-8116-9. PubMed PMID: 18338112.

26 Haji seyedJavadi AR, Shafikhani AA. Evaluation of depression and anxiety in patients with thalassemia: a comparative study. J Qazvin Univ Med Sci. 2017;21:13-21. Persian.
35 Ghaffari Saravi V, Zarghmi M, Ebrahimi E. The prevalence of depression in Thalassemic patients in the city of Sari. Iranian Journal of Psychiatry and Clinical Psychology. 2004;9:33-40.
36 Aziznejad P, Hosseni J, Shakerei J. Comparison between the frequency of depression among adolescents with and without thalassemia in Babol, 2007. Scientific Journal of Nursing, Midwifery and Paramedical Faculty. 2008;2:31-8. Persian.
37 Hashemi AS, Banaei-Boroujeni S, Kokab N. Prevalence of major depressive and anxiety disorders in hemophilic and major beta thalassemic patients. Iranian Journal of Pediatric Hematology and Oncology. 2012;2:11-6.
38 Marvasti VE, Dastoori P, Karimi M. Is beta-thalassemia trait a risk factor for developing depression in young adults? Ann Hematol. 2006;85:873-4. doi: 10.1007/s00277-006-0154-9. PubMed PMID: 16845515.
39 Yengil E, Acipayam C, Kokacya MH, Kurhan F, Oktay G, Ozer C. Anxiety, depression and quality of life in patients with beta thalassemia major and their caregivers. Int J Clin Exp Med. 2014;7:2165-72. PubMed PMID: 25232402; PubMed Central PMCID: PMC4161562.
40 Braam AW, Schrier AC, Tuinebreijer WC, Beekman AT, Dekker JJ, de Wit MA. Religious coping and depression in multicultural Amsterdam: a comparison between native Dutch citizens and Turkish, Moroccan and Surinamese/Antillean migrants. J Affect Disord. 2010;125:269-78. doi: 10.1016/j.jad.2010.02.116. PubMed PMID: 20334926.
41 Juhasz G, Eszlni N, Pap D, Gonda X. Cultural differences in the development and characteristics of depression. Neuropsychopharmacol Hung. 2012;14:259-65. PubMed PMID: 23269213.
42 Griffiths KM, Crisp DA, Jorm AF, Christiansen H. Does stigma predict a belief in dealing with depression alone? J Affect Disord. 2011;132:413-7. doi: 10.1016/j.jad.2011.03.012. PubMed PMID: 21440305.
43 Yang F, Yang BX, Stone TE, Wang XQ, Zhou Y, Zhang J, et al. Stigma towards depression in a community-based sample in China. Compr Psychiatry. 2020;97:152152. doi: 10.1016/j.comppsych.2019.152152. PubMed PMID: 31838297.
44 Mohamadi M, Mohaqeqi Kamal SH, Vameghi M, Rafiey H, Setareh Forouzan A, Sajjadi H. A meta-analysis of studies related prevalence of depression in Iran. Journal of Research and Health. 2017;7:581-93. doi: 10.18869/acadpub.jrh.7.1.581.
45 Borras L, Constant EL. Depression and beta-thalassemia: a genetic link? Acta Neuropsychiatrica. 2007;19:134. doi: 10.1111/j.1601-5215.2006.00180.x.
46 Koutelekos J, Haliasos N. Depression and Thalassemia in children, adolescents and adults. Health Science Journal. 2013;7:239.
47 Munoz RF, Beardslee WR, Leykin Y. Major depression can be prevented. Am Psychol. 2012;67:285-95. doi: 10.1037/a0027666. PubMed PMID: 22583342; PubMed Central PMCID: PMC4533896.